NASDAQ: BGNE       Beigene Ltd Ads
Last Price Today's Change   Day's Range   Trading Volume
160.86   +2.71 (1.71%)  154.95 - 166.00  485,524


Avg Volume (4 weeks):455,972
4 Weeks Range:135.15 - 166.00
4 Weeks Price Volatility (%):
52 Weeks Range:34.36 - 166.00
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

  Be the first to like this.


1757  5791  414  600 

Top 10 Active Counters
 NVCN 0.122-0.012 
 FB 171.52-13.57 
 SPY 269.22-4.98 
 TVIX 8.55+1.67 
 MU 59.60-0.98 
 QQQ 166.05-4.97 
 EEM 48.51-0.70 
 UVXY 17.05+2.69 
 VXX 44.70+5.20 
 AMD 11.39-0.08 
Partners & Brokers